Search results
Showing 46 to 60 of 233 results for children's cancer
MRI-based technologies for assessing non-alcoholic fatty liver disease (DG50)
Evidence-based recommendations on MRI-based technologies for assessing non-alcoholic fatty liver disease
This guideline covers diagnosis and management of thyroid cancer in people aged 16 and over. It aims to reduce variation in practice and increase the quality of care and survival for people with thyroid cancer.
Dr Sam Roberts, chief executive at NICE, looks back at NICE's achievements over the past year and discusses our priorities for 2023.
Our impact reports look at how the health and care system uses NICE's recommendations to improve people's health and care.
on people with a learning disability? Around 950,000 adults and 300,000 children in England have a learning disability. Many people with...
NICE's impact on transition from children’s to adults’ services
NICE's impact on innovative medicines for childhood conditions
This indicator covers the establishing and maintaining of a register of patients aged 18 or over with a BMI of 27.5 kg/m2 or more (or 30 kg/m2 or more if ethnicity is recorded as White) in the preceding 12 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM222
This indicator covers the establishing and maintaining of a register of patients aged 18 or over with a BMI of 23 kg/m2 or more (or 25 kg/m2 or more if ethnicity is recorded as White) in the preceding 12 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM221
This guideline covers care and treatment for adults (aged 18 and over) with type 1 diabetes. It includes advice on diagnosis, education and support, blood glucose management, cardiovascular risk, and identifying and managing long-term complications.
Evidence-based recommendations on ceftazidime with avibactam for treating severe drug-resistant gram-negative bacterial infections....
View recommendations for HTE1Show all sections
This guideline covers the assessment and management of melanoma (a type of skin cancer) in children, young people and adults. It aims to reduce variation in practice and improve survival.
Roxadustat for treating symptomatic anaemia in chronic kidney disease (TA807)
Evidence-based recommendations on roxadustat (Evrenzo) for treating symptomatic anaemia associated with chronic kidney disease in adults.
Setmelanotide for treating obesity caused by LEPR or POMC deficiency (HST21)
Evidence-based recommendations on setmelanotide (Imcivree) for treating obesity caused by LEPR or POMC deficiency in people 6 years and over.
The NICE real-world evidence framework aims to improve the quality of real-world evidence informing our guidance. The framework does not set minimum standards for the acceptability of evidence. The framework is mainly targeted at those developing evidence to inform NICE guidance. It is also relevant to patients, those collecting data, and reviewers of evidence
Show all sections
- Overview
- Introduction to real-world evidence in NICE decision making
- Conduct of quantitative real-world evidence studies
- Assessing data suitability
- Methods for real-world studies of comparative effects
- Appendix 1 - Data Suitability Assessment Tool (DataSAT)
- Appendix 2 - Reporting on methods used to minimise risk of bias
- Appendix 3 - Reporting information for selected analytical methods